Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Lenalidomide

Lenalidomide: 1 brand, 20 generics; first approved Dec 27, 2005; generic available.

Generic available12 exclusivity periodsHas discontinued products
Generic status & protection

Generic available: 20 ANDA applications approved.

Earliest patent expiry Latest exclusivity ends
Brands (NDA)
1
Generics (ANDA)
20
Listed patents
2
Next patent expiry
Apr 27, 2027
in 7 mo

Brand (NDA) products

Originator applications
  • NDA 02188020116 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
    2.5MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB

Generic (ANDA) products (20)

Abbreviated applications
  • LENALIDOMIDE
    ANDA 21340520266 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MGCAPSULEORALDiscontinued—
    25MGCAPSULEORALDiscontinued—
    20MGCAPSULEORALDiscontinued—
    15MGCAPSULEORALDiscontinued—
    2.5MGCAPSULEORALDiscontinued—
    5MGCAPSULEORALDiscontinued—
  • LENALIDOMIDE
    ANDA 21316520265 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 21887220256 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    2.5MGCAPSULEORALRxAB
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 21439820256 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    2.5MGCAPSULEORALRxAB
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 21755420256 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    2.5MGCAPSULEORALRxAB
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 21575920256 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    2.5MGCAPSULEORALRxAB
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 21621320256 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    2.5MGCAPSULEORALRxAB
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 21728120246 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    2.5MGCAPSULEORALRxAB
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 21726520246 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    2.5MGCAPSULEORALRxAB
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 21241420236 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    2.5MGCAPSULEORALRxAB
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 21102220236 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
    2.5MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 21048020236 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
    2.5MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 20145220236 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
    2.5MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 2146182023
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    2.5MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 21388520236 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    2.5MGCAPSULEORALRxAB
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 21391220236 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
    2.5MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 21184620236 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
    2.5MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 21015420236 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
    2.5MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 21043520225 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
  • LENALIDOMIDE
    ANDA 20934820216 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    2.5MGCAPSULEORALRxAB
    20MGCAPSULEORALRxAB
    5MGCAPSULEORALRxAB
    10MGCAPSULEORALRxAB
    15MGCAPSULEORALRxAB
    25MGCAPSULEORALRxAB

Patent & exclusivity timeline

Protection horizon
2026202720282029TodayExclusivity ODE-241: 2026-05-28Exclusivity ODE-241Exclusivity ODE-245: 2026-05-28Exclusivity ODE-245Exclusivity ODE-241: 2026-05-28Exclusivity ODE-241Exclusivity ODE-245: 2026-05-28Exclusivity ODE-245Exclusivity ODE-241: 2026-05-28Exclusivity ODE-241Exclusivity ODE-245: 2026-05-28Exclusivity ODE-245Exclusivity ODE-241: 2026-05-28Exclusivity ODE-241Exclusivity ODE-245: 2026-05-28Exclusivity ODE-245Exclusivity ODE-241: 2026-05-28Exclusivity ODE-241Exclusivity ODE-245: 2026-05-28Exclusivity ODE-245Exclusivity ODE-241: 2026-05-28Exclusivity ODE-241Exclusivity ODE-245: 2026-05-28Exclusivity ODE-245Patent 7465800: 2027-04-27Patent 7465800Patent 8741929: 2028-03-08Patent 8741929
Patent expiryExclusivity endToday

Marketing exclusivity

Hatch-Waxman
  • ODE-241Orphan-drug exclusivity (7 years)

    5 mo ago

  • ODE-245Orphan-drug exclusivity (7 years)

    5 mo ago

  • ODE-241Orphan-drug exclusivity (7 years)

    5 mo ago

  • ODE-245Orphan-drug exclusivity (7 years)

    5 mo ago

  • ODE-241Orphan-drug exclusivity (7 years)

    5 mo ago

  • ODE-245Orphan-drug exclusivity (7 years)

    5 mo ago

  • ODE-241Orphan-drug exclusivity (7 years)

    5 mo ago

  • ODE-245Orphan-drug exclusivity (7 years)

    5 mo ago

  • ODE-241Orphan-drug exclusivity (7 years)

    5 mo ago

  • ODE-245Orphan-drug exclusivity (7 years)

    5 mo ago

  • ODE-241Orphan-drug exclusivity (7 years)

    5 mo ago

  • ODE-245Orphan-drug exclusivity (7 years)

    5 mo ago

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
7465800in 7 mo
SubstanceProduct
8741929in 1 yr 5 mo
U-1983

Approval history

FDA approval span
First approval
21 yr 1 mo ago
Most recent approval
8 mo ago

Approvals span 2005–2026 across 21 FDA applications.

Brand (NDA) 15%
Generic (ANDA) 2095%

Lenalidomide: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Go beyond the database.

Try Assyro Intelligence for your regulatory research. Ready to discuss your team’s workflow? Book a demo.